Intervention

Palazestrant

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting2

Common conditions13

Lead sponsors shown1

Clinical trials

5 shown

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193 · 2024-12-16

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16

ACTIVE_NOT_RECRUITING

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerNCT05508906 · 2022-08-31

ACTIVE_NOT_RECRUITING

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsNCT05266105 · 2021-12-10

ACTIVE_NOT_RECRUITING

Common conditions

Breast Cancer4 Metastatic Breast Cancer4 ER Positive Breast Cancer2 HER2 Negative Breast Carcinoma2 Locally Advanced Breast Cancer2 Advanced Breast Cancer1 Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)1 Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)1 Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)1 ER-positive Breast Cancer1 Fulvestrant1 HER2-negative Breast Cancer1 Palazestrant1

Leading sponsors

Olema Pharmaceuticals, Inc.5

Trial status mix

ACTIVE_NOT_RECRUITING3

RECRUITING2

Phase mix

PHASE13

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.